Hillson, J., Mant, T., Ganguly, T., Rosano, M., Huntenburg, C., Alai-Safar, M., … Roach, J. (2016). FRI0182 A Single Dose Study Comparing Pharmacokinetics, Safety, and Immunogenicity of M923 (A Proposed Biosimilar To Adalimumab), US-Sourced Adalimumab, and EU-Sourced Adalimumab in Healthy Subjects. In Annals of the Rheumatic Diseases (Vol. 75, pp. 495.3-496). BMJ. https://doi.org/10.1136/annrheumdis-2016-eular.3706

Hillson, J., T. Mant, T. Ganguly, M. Rosano, C. Huntenburg, M. Alai-Safar, S. Darne, et al. “FRI0182 A Single Dose Study Comparing Pharmacokinetics, Safety, and Immunogenicity of M923 (A Proposed Biosimilar To Adalimumab), US-Sourced Adalimumab, and EU-Sourced Adalimumab in Healthy Subjects.” In Annals of the Rheumatic Diseases, 75:495.3-496. BMJ, 2016. https://doi.org/10.1136/annrheumdis-2016-eular.3706.

Hillson J, Mant T, Ganguly T, Rosano M, Huntenburg C, Alai-Safar M, et al. FRI0182 A Single Dose Study Comparing Pharmacokinetics, Safety, and Immunogenicity of M923 (A Proposed Biosimilar To Adalimumab), US-Sourced Adalimumab, and EU-Sourced Adalimumab in Healthy Subjects. In: Annals of the Rheumatic Diseases. BMJ; 2016. p. 495.3-496.

Hillson, J., et al. “FRI0182 A Single Dose Study Comparing Pharmacokinetics, Safety, and Immunogenicity of M923 (A Proposed Biosimilar To Adalimumab), US-Sourced Adalimumab, and EU-Sourced Adalimumab in Healthy Subjects.” Annals of the Rheumatic Diseases, vol. 75, no. Suppl 2, BMJ, 2016, pp. 495.3-496. Crossref, doi:10.1136/annrheumdis-2016-eular.3706.

Hillson J, Mant T, Ganguly T, Rosano M, Huntenburg C, Alai-Safar M, Darne S, Palmer D, Pavlova B, Doralt J, Reeve R, Goel N, Weilert D, Rhyne P, Caminis J, Roach J. FRI0182 A Single Dose Study Comparing Pharmacokinetics, Safety, and Immunogenicity of M923 (A Proposed Biosimilar To Adalimumab), US-Sourced Adalimumab, and EU-Sourced Adalimumab in Healthy Subjects. Annals of the Rheumatic Diseases. BMJ; 2016. p. 495.3-496.